Opus GeneticsvsMerck & Company

IRD and MRK stock compared: price, dividend, valuation and results, from SEC filings.

IRD

Opus Genetics, Inc.

$3.99

Value $386M

-2.21%
IRD's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Opus Genetics (IRD) has a market value of $386M and Merck & Company (MRK) $331B. Over the last year, with dividends, IRD moved +114.5% and MRK +44.8%. Dividend yield: IRD none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    IRD$386M

    MRK$331B

    MRK is 857 times IRD

  • Revenue, 12 months

    IRD$7.9M

    MRK$67.4B

    MRK is 8,514 times IRD

  • Net income, 12 months

    IRD-$137M

    MRK$2.5B

  • Operating margin

    IRD-777.7%

    MRK–

  • ROIC

    IRD-221.2%

    MRK3.9%

    225.1 points apart

  • P/E

    IRD–

    MRK134.8

  • Dividend yield

    IRD0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    IRD+9.6%

    MRK+93.0%

    83.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

IRD+9.7%

MRK+93.0%

10020020222023202420252026
Returns by period
PeriodIRDWith dividendsMRKWith dividends
1 year since November 19, 2025+114.5%Price +114.5%+44.8%Price +40.7%
3 years since November 20, 2023+37.6%+11.2% a yearPrice +37.6%+42.7%+12.6% a yearPrice +30.2%
5 years since November 19, 2021+9.6%+1.9% a yearPrice +9.6%+93.0%+14.1% a yearPrice +65.7%
10 years since November 22, 2016-95.4%-26.5% a yearPrice -95.4%+208.2%+11.9% a yearPrice +127.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

IRDOpus GeneticsMRKMerck & Company

Valuation

IRDMRK
Valuation
Price$3.99$133.72
Market value$386M$331B
Enterprise value (EV)$332M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B10.07.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

IRDMRK
Results and growth
Revenue, 12 months$7.9M$67.4B
Net income, 12 months-$137M$2.5B
Free cash flow, 12 months-$49M$14.7B
Earnings per share, 12 months-$1.56$0.98
Revenue growth, year on year29.2%1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

IRDMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-777.7%–
Net margin-1,726.7%3.6%
ROIC-221.2%3.9%
ROE–5.2%

Balance sheet

IRDMRK
Balance sheet
Cash$89M$9.7B
Total debt$36M$53.8B
Net debt / EBITDA–5.7
Interest cover-217.5×2.4×

Dividends and buybacks

IRDMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: IRD or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Opus Genetics or Merck & Company?

By market value, Merck & Company ($331B) is about 857.3 times Opus Genetics ($386M), at today's prices.

How did IRD and MRK stock do over the last 10 years?

Since November 22, 2016, IRD's price moved -95.4% and MRK's +127.1%. With dividends: IRD -95.4% (-26.5% a year), MRK +208.2% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, IRD or MRK?

The dividend yield at today's price is none for Opus Genetics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Opus Genetics or Merck & Company?

Over the last twelve months, the net margin was -1,726.7% for Opus Genetics and 3.6% for Merck & Company, and the operating margin -777.7% and –. Revenue was $7.9M and $67.4B.

Which is the better investment, Opus Genetics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.